CCR2 and melanoma: On the basis of this, a phase I clinical trial (NCT02723006) evaluating the combination of CCR2 inhibitors and nivolumab in the treatment of advanced melanoma is ongoing to verify the synergistic effect of combined blockade of CCR2 and immune checkpoints in activating CD8+ T cells and overcoming immunosuppression (209).